GSK’s MenABCWY vaccine is an injectable suspension intended for intramuscular use. It comes with a vial of lyophilised ...

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...

Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

GSK’s 5-in-1 meningococcal vaccine, Penmenvy receives US FDA approval to help protect against MenABCWY: London, UK Monday, February 17, 2025, 10:00 Hrs [IST] GSK plc announced t ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

The vaccine is to combine GSK’s injectable polio vaccine (IPV) and Biological E’s pentavalent vaccine for diphtheria, tetanus, whooping cough (whole cell pertussis), hepatitis B, and ...

notably twice-yearly injectable Sunlenca (lenacapavir) for multidrug-resistant (MDR) HIV infection, which was approved by the FDA in 2022 and is also being tested for PrEP. At AIDS 2024, GSK also ...

The company's long-acting injectable treatment Cabenuva and PrEP drug Apretude played a role in the growth. With the new sales target set and pipeline progressing, GSK on Wednesday also announced ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines. The University of Oxford and GSK are to work on a vaccine to target cells in the ...

GSK itself is trying to develop a twice-yearly ... Redfern noted that 63% of individuals in lenacapavir’s Purpose 2 trial developed injection-site nodules—including seven cases of ulcer ...

Please consult the full Summary of Product Characteristics for all the safety information: Rekambys 600mg/900 mg prolonged-release suspension for injection Trademarks are owned by or licensed to the ...